Levictus 500 Tablet contains Levetiracetam 500 mg, an antiepileptic medication primarily indicated for the treatment of partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby reducing neuronal excitability and seizure propagation. Levictus 500 is prescribed as adjunctive therapy or monotherapy depending on the clinical scenario and patient response. The tablet should be administered orally, with or without food, as directed by a healthcare professional. Dosage adjustments may be necessary in patients with renal impairment to prevent accumulation and toxicity. Common adverse effects include somnolence, dizziness, fatigue, and behavioral changes such as irritability or mood swings; however, serious adverse reactions are rare. It is essential to monitor patients for any neuropsychiatric symptoms and adjust therapy accordingly. Levictus 500 should be used cautiously in pregnant or breastfeeding women, and its use must be evaluated against potential risks and benefits. Patients are advised not to discontinue therapy abruptly to avoid increased seizure frequency. Overall, Levictus 500 Tablet offers an effective and well-tolerated option for seizure management under appropriate medical supervision.